In the subgroup analysis, T2D patients who were on insulin therapy showed a longer disease duration (11.4 ± 7.1 vs. 2.5 ± 3.1, P = 0.001) and a higher serum glucose level (185.0 ± 67.2 vs. 129.1 ± 23.2, P = 0.021). Here, INS is linked to type 2 diabetes mellitus.